In contrast, there is considerable excitement around the ability of RPT to overcome radioresistance through delivering alpha particle therapy (e.g., Ra‐223 for bone metastasis and Ac‐225‐PSMA for prostate cancer). The gene discussed is FOLH1; the disease is Familial prostate cancer.